Elan Spinoff Of Prothena Set For This Week, Will Trade Under PRTA Ticker
Elan (ELN) shareholders approved the separation of its drug discovery business, Prothena, at an Extraordinary General Meeting (EGM) last week. The company also released an updated timetable for the transaction and the distribution will take place on December 20th, with shareholders of Elan receiving 1 share of Prothena for every 41 shares of Elan owned as of the… Read More »